Overall, skimmianine’s dual targeting of PCNA and TNF-α modulates the immune TME, highlighting its potential as a regulator of immune dynamics in breast cancer by simultaneously reversing immune suppression and mitigating tumor-promoting inflammation. Here, TNF is linked to breast carcinoma.